Características farmacocinéticas diferenciales de micafungina. Experiencia en poblaciones especiales | Enfermedades Infecciosas y Microbiología Clínica

Article information

Resumen

En la actualidad se dispone de 3 equinocandinas para el tratamiento de infecciones fúngicas. Micafungina ha representado la última incorporación a este grupo de antifúngicos. A pesar de presentar un mecanismo de acción similar, esta molécula tiene algunas características farmacocinéticas distintas a las del resto del grupo. Hoy en día se dispone de amplia información acerca del comportamiento farmacocinético de micafungina procedente, fundamentalmente, de los pacientes incluidos en los ensayos clínicos. Sin embargo, el conocimiento de la farmacocinética de esta equinocandina en poblaciones especiales es mucho más limitado. El objetivo de la presente revisión es analizar la información disponible sobre la farmacocinética de micafungina en pediatría, pacientes ancianos, insuficiencia renal, insuficiencia hepática y en pacientes trasplantados.

Palabras clave:

Micafungina

Farmacocinética

Pediatría

Ancianos

Insuficiencia renal

Insuficiencia hepática

Trasplante

Keywords:

Micafungin

Pharmacokinetics

Pediatrics

The elderly

Renal insufficiency

Liver failure

Transplantation

Abstract

Currently, three echinocandins are available for the treatment of fungal infections. Micafungin is the latest drug to be incorporated into this group of antifungal agents. Although the mechanism of action of micafungin is similar to that of other echinocandins, this molecule has certain pharmacokinetic characteristics that distinguish it from other drugs in this group. Nowadays, there is wide information on the pharmacokinetic behavior of micafungin, mainly from patients included in clinical trials. However, there is far less knowledge of the pharmacokinetics of this echinocandin in special populations. The aim of the current review was to analyze the available information on the pharmacokinetics of micafungin in pediatric patients, the elderly, patients with renal insufficiency or liver failure, and transplant recipient.

Full text is only aviable in PDF

Bibliografía

[1.]

I. Poggesi, M. Strolin Benedetti, R. Whomsley, S. Le Lamer, M. Molimard, J.B. Watelet.

Pharmacokinetics in special populations.

Drug Metabolism Reviews, 41 (2009), pp. 422-454

http://dx.doi.org/10.1080/10837450902891527 | Medline

[2.]

W.A. Craig.

Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

Clin Infect Dis, 26 (1998), pp. 1-10

Medline

[3.]

H.L. VandenBussche, D.A. Van Loo.

A clinical review of echinocandins in pediatric patients.

Ann Pharmacother, 44 (2010), pp. 166-177

http://dx.doi.org/10.1345/aph.1M139 | Medline

[4.]

N. Seibel, C. Schwartz, A. Arrieta, P. Flynn, A. Shad, E. Albano, et al.

Safety, tolerability, and pharmacokinetics of micafungin (FK463) in febril neutropenic pediatric patients.

Antimicrobial Agents Chemother, 49 (2005), pp. 3317-3324

[5.]

N. Ashouri, J. Singh, A. Arrieta.

Micafungin in pediatrics: when one sizes does not fit all.

Expert Opin Drug Metabol Toxicol, 4 (2008), pp. 463-469

[6.]

W.W. Hope, N.L. Seibel, C.L. Schwartz, A. Arrieta, P. Flynn, A. Shad, et al.

Population pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosing.

Antimicrob Agents Chemother, 51 (2007), pp. 3714-3719

http://dx.doi.org/10.1128/AAC.00398-07 | Medline

[7.]

G.P. Heresi, D.R. Gerstmann, M.D. Reed, J.N. Van den Anker, J.L. Blumer, L. Kovanda, et al.

The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants.

Pediatr Infect Dis. J, 25 (2006), pp. 1110-1115

http://dx.doi.org/10.1097/01.inf.0000245103.07614.e1 | Medline

[8.]

D.K. Benjamin Jr., P.B. Smith, A. Arrieta, L. Castro, P.J. Sánchez, D. Kaufman, et al.

Safety and pharmacokinetics of repeat-dose micafungin in young infants.

Clin Pharmacol Ther, 87 (2010), pp. 93-99

http://dx.doi.org/10.1038/clpt.2009.200 | Medline

[9.]

P.B. Smith, T.J. Walsh, W. Hope, A. Arrieta, A. Takada, L.L. Kovanda, et al.

Pharmacokinetics of an elevated dosage of micafungin in premature neonates.

Pediatr Infect Dis J, 28 (2009), pp. 412-415

http://dx.doi.org/10.1097/INF.0b013e3181910e2d | Medline

[10.]

W.W. Hope, P.B. Smith, A. Arrieta, D.N. Buell, M. Roy, A. Kaibara, et al.

Population pharmacokinetics of micafungin in neonates and young infants.

Antimicrob Agents Chemother, 54 (2010), pp. 2633-2637

http://dx.doi.org/10.1128/AAC.01679-09 | Medline

[11.]

N.P. Wiederhold, J.S. Lewis II.

The echinocandin micafungin: a review of the pharmacology, spectrum of activity, clinical efficacy and safety.

Expert Opin Pharmacother, 8 (2007), pp. 1155-1166

http://dx.doi.org/10.1517/14656566.8.8.1155 | Medline

[12.]

M. Catalán-González, J.C. Montejo-González.

Pharmacodynamics and pharmacokinetics of micafungin in adults, children and neonate.

Rev Iberoam Micol, 26 (2009), pp. 23-34

http://dx.doi.org/10.1016/S1130-1406(09)70005-1 | Medline

[13.]

T. Mukai, T. Ohkuma, K. Nakahara, T. Takaya, T. Uematsu, J. Azuma.

Pharmacokinetics of FK463, a novel echinocandin analogue, in elderly and non-elderly subjects.

41st Interscience Conference on Antimicrobial Agents and Chemotherapy,

[14.]

C. Wagner, W. Graninger, Joukhadar C. Presterl.

The echinocandins: comparison of their pharmacokinetics, pharmadodynamics and clinical applications.

Pharmacology, 78 (2006), pp. 161-177

http://dx.doi.org/10.1159/000096348 | Medline

[15.]

J.M. Joseph, R. Jain, L.H. Danziger.

Micafungin: a new echinocandin antifungal.

Pharmacotherapy, 27 (2007), pp. 53-67

http://dx.doi.org/10.1592/phco.27.1.53 | Medline

[16.]

M.F. Hebert, H.E. Smith, T.C. Marbury, S.K. Swan, W.B. Smith, R.W. Townsend, et al.

Pharmacokinetics of micafungin in healthy volunteers, volunteers with moderate liver disease, and volunteers with renal dysfunction.

J Clin Pharmacol, 45 (2005), pp. 1145-1152

http://dx.doi.org/10.1177/0091270005279580 | Medline

[17.]

T. Yokote, T. Akioka, S. Oka, T. Fujisaka, T. Yamano, S. Hara, et al.

Successful treatment with micafungin of invasive pulmonary aspergillosis in acute mieloide leucemia, with renal failure due to amphotericin B therapy.

Ann Hematol, 83 (2004), pp. 64-66

http://dx.doi.org/10.1007/s00277-003-0736-8 | Medline

[18.]

K. Hirata, T. Aoyama, Y. Matsumoto, F. Ogawa, H. Yamazaki, Kikuti, et al.

Pharmacokinetics of antifungal agent micafungin in critically ill patients receving continuous hemodiálisis filtration.

Yakugaku Zasshi, 127 (2007), pp. 897-901

Medline

[19.]

H. Konishi, M. Sudo, M. Sumi, H. Morii, T. Minouchi, T. Aimoto, et al.

Pharmacokinetic behavior of micafungin in rats with cabon tetrachloride-induced acute hapatic failure.

Biol Pharm Bull, 28 (2005), pp. 556-559

Medline

[20.]

H. Konishi, K. Fukushima, M. Sudo, M. Sumi, T. Minouchi, I. Iga, et al.

Reduced elimitation clearance of micafungin in rats with cholestatic hyperbilirubinemia.

Fundam Clin Pharmacol, 24 (2009), pp. 457-462

http://dx.doi.org/10.1111/j.1472-8206.2009.00785.x | Medline

[21.]

J. Hiemenz, P. Cagnoni, D. Simpson, S. Devine, N. Chao, J. Keirns, et al.

Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant.

Antimicrob Agents Chemother, 49 (2005), pp. 1331-1336

http://dx.doi.org/10.1128/AAC.49.4.1331-1336.2005 | Medline

[22.]

Y. Muraki, T. Iwamoto, Y. Kagawa, H. Sakurai, M. Usui, S. Isaji, et al.

The impact of total bilirubin on plasma micafungin levels in living-donor transplantation recipients with severe liver dysfunction.

Biol Pharm Bull, 32 (2009), pp. 750-754

Medline

[23.]

N. Mouchizuki, K. Matsumoto, K. Ohno, T. Shimamura, H. Furukawa, S. Todo, et al.

Effects of hepatic CYP3A4 activity on disposition of micafungin in liver transplant recipients with markedly small-for-size grafts.

Transplant Proc, 38 (2006), pp. 3649-3650

http://dx.doi.org/10.1016/j.transproceed.2006.10.146 | Medline